Maintenance therapy involving a tapering dose of danazol or mid/low doses of oral contraceptive after gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain

article OA: closed CC0 ⤵ 21 in-corpus citations
AI-generated summary by gemini-2.5-flash-lite, 2026-06-07

This study compared maintenance therapies with tapering danazol or oral contraceptives after GnRH agonist treatment for endometriosis-associated pelvic pain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Pelvic pain associated with endometriosis was treated by the long-term administration of a tapering dose of danazol or mid/low doses of oral contraceptives after the end of therapy involving a GnRH agonist (GnRH-a). Results demonstrated that each of these three therapies is a practical and efficient treatment regimen to maintain the relief of pelvic pain achieved by GnRH-a therapy, at least for a period of 12 months.

My notes (saved in your browser only)

Condition tags

dysmenorrheaendometriosischronic_pelvic_pain

MeSH descriptors

Contraceptives, Oral Danazol Endometriosis Estrogen Antagonists Gonadotropin-Releasing Hormone Pelvic Pain CA-125 Antigen CA-125 Antigen Contraceptives, Oral Danazol Dysmenorrhea Dysmenorrhea Endometriosis Endometriosis Estrogen Antagonists Female Gonadotropin-Releasing Hormone Humans Pelvic Pain Pelvic Pain

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (20)

Cited by (21)

Source provenance

europepmc
last seen: 2026-09-01T06:12:48.306406+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:14:48.452140+00:00
unpaywall
last seen: 2026-08-15T06:29:46.044917+00:00
License: CC0 · commercial use OK